Our partner’s ambition is to harness the power of peptide conjugation technologies to address the delivery challenge associated with nucleic acid therapeutics and thus realize the clinical potential of these transformative therapeutics. There is a deep need for a paradigm shift in genomic medicine, and our partner’s innovative peptides are ideally positioned to effect this change for patients, families, and the broader healthcare community.

This critical hire was responsible for all aspects of the quality function within the company, including leading the quality strategy and culture, development, and implementation of a quality management system (QMS) to ensure GMP, GLP and GCP compliance for the company’s IND-enabling activities and clinical-stage programs and associated CDMOs, CROs and other vendors.